Edition:
United States

Celsion Corp (CLSN.O)

CLSN.O on Consolidated Issue listed on NASDAQ Capital Market

0.30USD
29 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.30
Open
$0.28
Day's High
$0.31
Day's Low
$0.28
Volume
1,884,228
Avg. Vol
2,011,188
52-wk High
$1.78
52-wk Low
$0.19

Latest Key Developments (Source: Significant Developments)

Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy
Monday, 27 Feb 2017 08:30am EST 

Celsion Corp : Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy at the ASCO-SITC clinical immuno-oncology symposium . Celsion Corp - in first twelve patients dosed in ovation study, GEN-1 plus standard chemotherapy produced impressive clinical results . Celsion Corp - Celsion expects to complete enrollment and treatment phase of ovation study early in Q2 .Celsion - expects to report final data from ovation study , including translational data for all patients, by end of Q2 of 2017.  Full Article

Celsion files for offering of up to $15 mln in shares of common stock and base warrants
Friday, 23 Dec 2016 03:04pm EST 

Celsion Corp : Files for offering of up to $15 million in shares of common stock and base warrants - SEC filing .Says shares of its common stock and base warrants are immediately separable and will be issued separately, but will be purchased together in the offering.  Full Article

Celsion posts Q2 loss of $0.19/share
Monday, 15 Aug 2016 09:00am EDT 

Celsion Corp: Celsion Corporation reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.19 .Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 09:00am EDT 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Celsion expects to report translational data from first two cohorts of ovation study in Q3
Tuesday, 24 May 2016 08:00am EDT 

Celsion Corp : Celsion Corp Says Has Completed Enrollment Of Second Cohort Of Ovation Study And Expects To Report Clinical Data From That Cohort Mid Year . Celsion Corp says also expects to report translational data from first two cohorts of ovation study early in Q3 of 2016 .Celsion announces presentation of ovation study clinical trial design at upcoming asco 2016 meeting.  Full Article

Celsion Corp Q1 loss per share $0.24
Monday, 16 May 2016 08:21am EDT 

Celsion Corp : Celsion corporation reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.24 .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Celsion receives CFDA approval to conduct OPTIMA study in China
Wednesday, 16 Dec 2015 08:00am EST 

Celsion Corp:Announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct the ongoing Phase III OPTIMA Study at clinical sites in China.  Full Article

Celsion Corp announces preclinical data of ovarian cancer drug
Monday, 12 Oct 2015 08:00am EDT 

Celsion Corp:Announces impressive preclinical data for its gen-1 il-12 immunotherapy in combination with avastin® and doxil® for ovarian cancer.Says phase 1/2 combination trial is expected to begin in mid-2016.Results show gen-1 when combined with avastin,doxil,showed greater than 98% reduction in tumor burden when compared to untreated control group.  Full Article

Celsion presents gen-1 immunotherapy phase 1b results in recurrent ovarian cancer
Monday, 1 Jun 2015 08:00am EDT 

Celsion Corp:Presents gen-1 immunotherapy phase 1b results in recurrent ovarian cancer at asco 2015.Says significant clinical benefit observed at highest dose of gen-1 in platinum resistant ovarian cancer.Gen-1 was well tolerated, with no dose limiting toxicities and no overlapping toxicities between gen-1 and pegylated doxorubicin.Since maximum tolerated dose was not reached, co to evaluate gen-1 in phase 1 dose escalating trial in first line neoadjuvant ovarian cancer.Plans to initiate phase 1b dose escalating trial evaluating gen-1 plus avastin and doxil in platinum-resistant ovarian cancer patients.  Full Article

Celsion Corp announces $8 mln at-the-market registered direct offering
Thursday, 28 May 2015 08:45am EDT 

Celsion Corp:Says two institutional healthcare investors to purchase an aggregate of about $8 mln of common stock in a direct offering and a concurrent private placement of warrants to purchase common stock.Enters into a definitive purchase agreement with these investors pursuant to which the Company agreed to sell an aggregate of 3,000,000 shares of its common stock at a per share price of $2.675 in a registered direct offering.To issue to the investors warrants to purchase, for each share of common stock purchased in the registered direct offering, 0.65 share of common stock for a total of 1,950,000 shares of common stock.Warrants have an exercise price of $2.60 per share and will expire five years from the date of issuance.Closing of the registered direct offering and the concurrent private placement is expected to take place on or about June 1.Net proceeds to the Company from the sale of the shares of common stock in the registered direct offering are expected to be about $7.3 mln.Intends to use the net proceeds for general corporate purposes.Maxim Group LLC is acting as sole placement agent in connection with the registered direct offering and concurrent private placement.  Full Article

More From Around the Web

BRIEF-Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy

* Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy at the ASCO-SITC clinical immuno-oncology symposium